The CYCC chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the CYCC chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The CYCC stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View CYCC Detailed Price Forecast - CNN Money | View CYCC Detailed Summary - Google Finance | ||
View CYCC Detailed Summary - Yahoo! Finance | View CYCC Stock Research & Analysis - Zacks.com |
View CYCC Trends & Analysis - Trade-Ideas | View CYCC Major Holders - Barrons | ||
View CYCC Call Transcripts - NASDAQ | View CYCC Breaking News & Analysis - Seeking Alpha | ||
View CYCC Annual Report - CompanySpotlight.com | View CYCC OTC Short Report - OTCShortReport.com | ||
View CYCC Fundamentals - TradeKing | View CYCC SEC Filings - Bar Chart | ||
View Historical Prices for CYCC - The WSJ | View Performance/Total Return for CYCC - Morningstar | ||
View the Analyst Estimates for CYCC - MarketWatch | View the Earnings History for CYCC - CNBC | ||
View the CYCC Earnings - StockMarketWatch | View CYCC Buy or Sell Recommendations - MacroAxis | ||
View the CYCC Bullish Patterns - American Bulls | View CYCC Short Pain Metrics - ShortPainBot.com |
View CYCC Stock Mentions - StockTwits | View CYCC Stock Mentions - PennyStockTweets | ||
View CYCC Stock Mentions - Twitter | View CYCC Investment Forum News - Investor Hub | ||
View CYCC Stock Mentions - Yahoo! Message Board | View CYCC Stock Mentions - Seeking Alpha |
View Insider Transactions for CYCC - SECform4.com | View Insider Transactions for CYCC - Insider Cow | ||
View CYCC Major Holdings Summary - CNBC | View Insider Disclosure for CYCC - OTC Markets | ||
View Insider Transactions for CYCC - Yahoo! Finance | View Institutional Holdings for CYCC - NASDAQ |
View CYCC Stock Insight & Charts - FinViz.com | View CYCC Investment Charts - StockCharts.com | ||
View CYCC Stock Overview & Charts - BarChart | View CYCC User Generated Charts - Trading View |
Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer
Posted on Monday April 01, 2024
- New clinical, PK and PD data from novel CDK2/9 inhibitor fadraciclib monotherapy studies support ongoing development program in patients with solid tumors and lymphoma - BERKELEY HEIGHTS, N.J., April 01, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that new clinical, pharmacokinetic (PK) and pharmacodynamic (PD) data fr
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript
Posted on Wednesday March 20, 2024
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q4 2023 Earnings Call Transcript March 19, 2024 Cyclacel Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-6.23, expectations were $-6.35. CYCC isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to the […]
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Posted on Tuesday March 19, 2024
– On Track to Start Oral Fadraciclib Phase 2 Proof of Concept in 1H 2024 – – Expect to Report Final Data from Fadraciclib 065-101 Dose Escalation – – Oral Plogosertib Preclinical Data Support Precision Medicine Strategy in ARID1A- and SMARCA-Mutated Cancers – – Management to Host Conference Call at 4:30 pm ET Today – BERKELEY HEIGHTS, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company dev
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results
Posted on Wednesday March 13, 2024
BERKELEY HEIGHTS, N.J., March 13, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce fourth quarter and full year 2023 financial results on Tuesday, March 19, 2024. The Company will host a conference call at 4:30pm ET on the same day. Conference call information: Participant Toll-Free Number: 800-579-2543 Primary Participant Dire